Shulman DeMeo Asset Management’s GSK GSK Stock Holding History

Shulman DeMeo Asset Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$317K	Sell	6,042 -100	-2%	-$5.29K	0.06%	111
2026 Q1	$339K	Buy	+6,142	New	+$333K	0.07%	97
2022 Q3	–	Sell	-8,611	Closed	-$469K	–	132
2022 Q2	$469K	Buy	8,611 +393	+5%	+$21.7K	0.16%	63
2022 Q1	$447K	Buy	8,218 +34	+0.4%	+$1.85K	0.12%	81
2021 Q4	$451K	Buy	+8,184	New	+$426K	0.12%	78
2021 Q3	–	Sell	-7,832	Closed	-$390K	–	102
2021 Q2	$390K	Buy	7,832 +34	+0.4%	+$1.63K	0.15%	43
2021 Q1	$348K	Buy	7,798 +3	+0%	+$136	0.09%	98
2020 Q4	$359K	Buy	7,795 +73	+0.9%	+$3.35K	0.1%	92
2020 Q3	$363K	Sell	7,722 -245	-3%	-$12.3K	0.12%	78
2020 Q2	$406K	Sell	7,967 -446	-5%	-$22.9K	0.16%	65
2020 Q1	$398K	Sell	8,413 -553	-6%	-$29.5K	0.19%	54
2019 Q4	$527K	Sell	8,966 -216	-2%	-$12K	0.18%	61
2019 Q3	$490K	Buy	9,182 +24	+0.3%	+$1.24K	0.16%	64
2019 Q2	$458K	Buy	9,158 +30	+0.3%	+$1.5K	0.17%	63
2019 Q1	$477K	Buy	9,128 +26	+0.3%	+$1.3K	0.18%	57
2018 Q4	$435K	Buy	+9,102	New	+$448K	0.24%	37

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Shulman DeMeo Asset Management's GSK Position: Q2 2026 in Review

Shulman DeMeo Asset Management reduced its GSK (GSK) stake by 1.6% in Q2 2026, selling an estimated $5.29K and leaving 6,042 shares worth $317K. The position accounts for 0.06% of the portfolio, ranked #111.

Shulman DeMeo Asset Management first reported a position in GSK in Q4 2018 and has held it in 16 quarters since. The position peaked at $527K in Q4 2019. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Shulman DeMeo Asset Management held 6,042 shares of GSK worth $317K as of Q2 2026.
Shulman DeMeo Asset Management sold 100 GSK shares in Q2 2026, an estimated $5.29K.
GSK made up 0.06% of Shulman DeMeo Asset Management's portfolio in Q2 2026, its #111 holding.
Shulman DeMeo Asset Management first reported a position in GSK in Q4 2018 and has held it in 16 quarters since.
Shulman DeMeo Asset Management's GSK position peaked at $527K in Q4 2019.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Shulman DeMeo Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.